This week, we have a conversation with Dylan Yeo, CEO and co-founder of Klona Biotech about 3D printing of regenerative implants, and we chat with Joana Correia, CEO, CSO, and co-founder of Exogenus Therapeutics, about a new consortium leading the way on secretomes.
Times: 03:28 Klona Biotech
25:30 Exogenus Therapeutics
Klona Biotech
Klona is developing the first bioprinting system specifically designed to print regenerative implants for fibrous human tissues.
Its bioprinting system integrates in-house developed software, hardware, and material science to produce constructs that replicate the fibrous microarchitecture of structural tissues and the necessary strength and flexibility for their function.
Its goal is to create the necessary manufacturing layer to 3D print whole human tissues on demand for grafts and transplants.
Exogenus Therapeutics
The ExoCordOA consortium recently launched a five-year, €13m project to advance extracellular vesicle-enriched secretome therapies towards clinical use, with an initial focus on osteoarthritis.
Led by Exogenus Therapeutics, ExoCordOA brings together 10 organisations with complementary expertise across different disciplines. The consortium will support the development of a new secretome-based medicine for osteoarthritis and help build the foundations for Europe’s leadership in secretome-based therapeutics.
A central objective is to advance Exogenus’ lead candidate, EXO-101, towards clinical validation as a potential disease-modifying treatment for osteoarthritis. The programme will support clinical development while also addressing key scientific, manufacturing, quality-control and regulatory challenges that currently limit the clinical translation of extracellular vesicle and secretome therapies.
The consortium aims to resolve systemic bottlenecks by helping to develop more standardised approaches, robust analytical and potency assessment methods, and a clearer regulatory pathway for future secretome-based medicines.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com